New EU Pharmacovigilance Law To Pass This Year

BMI view: The proposed strengthening of the EU's safety monitoring for pharmaceuticals could lead to more rapid withdrawal of products that present an unacceptable level of risk. We would therefore expect downside risks to drugmakers' sales.

To read the full article, please choose one of the following options: